- Home
- ELBM vs CYTH Comparison
ELBM vs CYTH Comparison
Compare ELBM & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- CYTH
- Stock Information
- Founded
- ELBM 2011
- CYTH 1990
- Country
- ELBM Canada
- CYTH United States
- Employees
- ELBM N/A
- CYTH N/A
- Industry
- ELBM Industrial Machinery/Components
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- CYTH Health Care
- Exchange
- ELBM Nasdaq
- CYTH Nasdaq
- Market Cap
- ELBM 24.9M
- CYTH 20.4M
- IPO Year
- ELBM N/A
- CYTH N/A
- Fundamental
- Price
- ELBM $0.38
- CYTH $0.63
- Analyst Decision
- ELBM Strong Buy
- CYTH Buy
- Analyst Count
- ELBM 1
- CYTH 3
- Target Price
- ELBM $1.30
- CYTH $0.95
- AVG Volume (30 Days)
- ELBM 70.1K
- CYTH 43.6K
- Earning Date
- ELBM 11-15-2024
- CYTH 11-14-2024
- Dividend Yield
- ELBM N/A
- CYTH N/A
- EPS Growth
- ELBM N/A
- CYTH N/A
- EPS
- ELBM N/A
- CYTH N/A
- Revenue
- ELBM N/A
- CYTH $870,725.00
- Revenue This Year
- ELBM N/A
- CYTH N/A
- Revenue Next Year
- ELBM $1,630.56
- CYTH $24.49
- P/E Ratio
- ELBM N/A
- CYTH N/A
- Revenue Growth
- ELBM N/A
- CYTH N/A
- 52 Week Low
- ELBM $0.26
- CYTH $0.57
- 52 Week High
- ELBM $0.75
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- ELBM 26.92
- CYTH 46.82
- Support Level
- ELBM $0.41
- CYTH $0.60
- Resistance Level
- ELBM $0.45
- CYTH $0.69
- Average True Range (ATR)
- ELBM 0.03
- CYTH 0.04
- MACD
- ELBM -0.00
- CYTH 0.00
- Stochastic Oscillator
- ELBM 4.57
- CYTH 50.00
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.